Several analysts have recently updated their ratings and price targets for AnaptysBio (NASDAQ: ANAB):

  • 9/7/2017 – AnaptysBio was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $34.00 price target on the stock. According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “
  • 9/6/2017 – AnaptysBio was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “
  • 8/30/2017 – AnaptysBio was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $28.00 price target on the stock. According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “
  • 8/29/2017 – AnaptysBio was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “
  • 8/25/2017 – AnaptysBio had its price target raised by analysts at Credit Suisse Group from $34.00 to $38.00. They now have an “outperform” rating on the stock.
  • 8/22/2017 – AnaptysBio was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $25.00 price target on the stock. According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “
  • 8/15/2017 – AnaptysBio was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $24.00 price target on the stock. According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “
  • 7/17/2017 – AnaptysBio was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “
  • 7/10/2017 – AnaptysBio is now covered by analysts at Robert W. Baird. They set an “outperform” rating and a $36.00 price target on the stock.

Shares of AnaptysBio, Inc. (ANAB) opened at 31.68 on Friday. The stock’s 50 day moving average is $24.43 and its 200 day moving average is $25.03. AnaptysBio, Inc. has a 1-year low of $15.17 and a 1-year high of $32.05. The company’s market cap is $644.43 million.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.29. The company had revenue of $7 million for the quarter, compared to analysts’ expectations of $3.45 million. On average, analysts predict that AnaptysBio, Inc. will post ($1.96) earnings per share for the current year.

In related news, major shareholder Holdings A/S Novo sold 70,706 shares of the stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $23.31, for a total transaction of $1,648,156.86. Following the completion of the transaction, the insider now owns 3,009,949 shares of the company’s stock, valued at approximately $70,161,911.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $24.35, for a total transaction of $901,924.00. The disclosure for this sale can be found here. Insiders have sold a total of 1,133,940 shares of company stock valued at $24,223,316 in the last ninety days.

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Receive News & Ratings for AnaptysBio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc and related companies with MarketBeat.com's FREE daily email newsletter.